Physiowave
Australia - MelbourneBiotechnology
Focus: Physiowave is an early-stage Australian biotech founded in 2024 focused on cardiovascular risk assessment through pulse wave velocity device technology. The company operates as a pre-revenue venture with minimal public disclosure on scale or market positioning.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Open Jobs
0
About Physiowave
AI assessmentNot HiringNo open roles listed right now. Follow Physiowave to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
1 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
PhysioWave Cardiovascular Analyzer
Cardiovascular Risk FactorClinical Trials (1)
NCT03126994Prospective, Single-Center, Non-Randomized Study of the PhysioWave™ Cardiovascular Analyzer
N/AHelp build intelligence for Physiowave
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.